SHANGHAI, Nov 12 (Reuters) – China has approved Eli Lilly's weight-loss pill orforglipron, the country's medicine regulator said on Thursday, giving the drugmaker a leg up on Danish rival Novo Nordisk
(The article has been published through a syndicated feed. Except for the headline, the content has been published verbatim. Liability lies with original publisher.)
By Wen-Yee Lee, Yimou Lee and Ben Blanchard TAIPEI, Nov 12 (Reuters) - Taiwan's Foxconn,…
Nov 12 (Reuters) - Wizz Air Holdings PLC: * WIZZ AIR HOLDINGS - HALF YEAR…
During the quarter, we added three new clients to our portfolio, further strengthening our commitment…
(Adds detail) NUSA DUA, Indonesia, Nov 12 (Reuters) - Indonesia's consumption of palm oil-based biodiesel…
SHANGHAI, Nov 12 (Reuters) - China has approved Eli Lilly's weight loss pill orforglipron, the country's…
By Aishwarya Venugopal and Alexandra Alper Nov 11 (Reuters) - Nvidia's board is meeting late…